"";"study";"condition_arm1";"condition_arm2";"multi_arm1";"multi_arm2";"outcome_type";"instrument";"rating";"instrument_symptom";"primary_instrument";"cov_time_point";"time";"time_weeks";"time_days";"primary_timepoint";"post_crossover";"n_arm1";"mean_arm1";"sd_arm1";"n_arm2";"mean_arm2";"sd_arm2";"n_change_arm1";"mean_change_arm1";"sd_change_arm1";"n_change_arm2";"mean_change_arm2";"sd_change_arm2";"event_arm1";"totaln_arm1";"event_arm2";"totaln_arm2";"baseline_m_arm1";"baseline_sd_arm1";"baseline_n_arm1";"baseline_m_arm2";"baseline_sd_arm2";"baseline_n_arm2";"d1";"d2";"d3";"d4";"d5";"rob";"year";"drug_arm1";"drug_arm2";"dose_arm1";"dose_arm2";"name_arm1";"name_arm2";"n_dosing_sessions";"mean_age";"percent_women";"diagnosis";"target_group";"design";"blinding";"doi";"registration_number";".id";".g";".g_se";".log_rr";".log_rr_se";".event_arm1";".event_arm2";".totaln_arm1";".totaln_arm2";"full_ref"
"1";"Back, 2024";"psil";"ncn";NA;NA;"msd";"madrs";"clinician";"depression";1;"Pre-first dose 1";-8;-1,14;-8;0;NA;15;27,67;5,27;15;28,4;7,39;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Low";"Low";"Low";"Low";"Low";2024;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin arm";"niacin arm";1;38;0,5;"dep";NA;"parallel";"double-blind";101001;5163496;"Back2024_msd_madrs_Day-8_-1.14_clinician_psil_ncn_NA_NA";0,110666088903096;0,365443493603394;NA;NA;NA;NA;NA;NA;"Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., & Gooley, T. A. (2024). Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic. JAMA Network Open, 7(12), e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026"
"2";"Back, 2024";"psil";"ncn";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 4";28;4;28;1;NA;15;6,33;6,72;15;19,07;10,34;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Low";"Low";"Low";"Low";"Low";2024;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin arm";"niacin arm";1;38;0,5;"dep";NA;"parallel";"double-blind";101001;5163496;"Back2024_msd_madrs_Day28_4.00_clinician_psil_ncn_NA_NA";1,42153552640956;0,410986356401838;NA;NA;NA;NA;NA;NA;"Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., & Gooley, T. A. (2024). Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic. JAMA Network Open, 7(12), e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026"
"3";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"change";"qids-sr";"self-report";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;30;-8;5,47722557505166;29;-6;5,3851648071345;NA;NA;NA;NA;14,5;3,9;30;16,4;4,1;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_change_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA";0,363309361758319;0,262611586674514;NA;NA;NA;NA;NA;NA;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"4";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"change";"bdi-1a";"self-report";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;30;-18,4;12,2958125154221;29;-10,8;9,6163657270259;NA;NA;NA;NA;29,1;6,8;30;28,7;7;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_change_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA";0,678018079704898;0,267986899585578;NA;NA;NA;NA;NA;NA;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"5";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"change";"ham-d-17";"clinician";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;30;-10,5;5,47722557505166;29;-5,1;5,3851648071345;NA;NA;NA;NA;19,2;2,3;30;18,4;3,4;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_change_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA";0,980935276747461;0,276026275889254;NA;NA;NA;NA;NA;NA;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"6";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"change";"madrs";"clinician";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;30;-14,4;9,31128347758782;29;-7,2;9,15478017212866;NA;NA;NA;NA;27,9;4;30;26,9;5,3;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_change_madrs_Week6_3.00_clinician_psil_esc_NA_NA";0,769361001370558;0,270125147933961;NA;NA;NA;NA;NA;NA;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"7";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"msd";"qids-sr";"self-report";"depression";1;"Post-second dose 1";6;3;21;1;NA;30;6,9;5,9;29;10,1;5,8;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14,5;3,9;30;16,4;4,1;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_msd_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA";0,539678732925694;0,265237432013847;NA;NA;NA;NA;NA;NA;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"8";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"msd";"bdi-1a";"self-report";"depression";0;"Post-second dose 1";6;3;21;1;NA;30;10,7;11;29;17,9;11,1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29,1;6,8;30;28,7;7;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_msd_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA";0,643016935967134;0,267235040715549;NA;NA;NA;NA;NA;NA;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"9";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"msd";"ham-d-17";"clinician";"depression";0;"Post-second dose 1";6;3;21;1;NA;30;8,3;5,5;29;13,6;5,2;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19,2;2,3;30;18,4;3,4;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_msd_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA";0,976697930755904;0,275895471772229;NA;NA;NA;NA;NA;NA;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"10";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"msd";"madrs";"clinician";"depression";0;"Post-second dose 1";6;3;21;1;NA;30;13;10;29;19,8;8,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27,9;4;30;26,9;5,3;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_msd_madrs_Week6_3.00_clinician_psil_esc_NA_NA";0,722027242067186;0,26898553479948;NA;NA;NA;NA;NA;NA;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"11";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"response";"qids-sr";"self-report";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;30;14;29;14,5;3,9;30;16,4;4,1;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_response_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA";0,498501201709367;0,300373270489182;0,371563556432483;0,226343824951325;21;14;30;29;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"12";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"remission";"qids-sr";"self-report";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;8;29;14,5;3,9;30;16,4;4,1;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_remission_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA";0,670992169548338;0,306156690535671;0,719870250700699;0,340598645707439;17;8;30;29;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"13";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"response";"bdi-1a";"self-report";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;30;12;29;29,1;6,8;30;28,7;7;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_response_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA";0,836678104294455;0,31598999314667;0,616686014465468;0,242889897379194;23;12;30;29;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"14";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"remission";"bdi-1a";"self-report";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;5;29;29,1;6,8;30;28,7;7;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_remission_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA";0,99934093835083;0,338703230909486;1,18987387994643;0,437043976571857;17;5;30;29;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"15";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"response";"ham-d-17";"clinician";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;30;7;29;19,2;2,3;30;18,4;3,4;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_response_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA";1,17335476888894;0,330230008279525;1,11123075262732;0,347124756186685;22;7;30;29;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"16";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"response";"madrs";"clinician";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;30;6;29;27,9;4;30;26,9;5,3;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_response_madrs_Week6_3.00_clinician_psil_esc_NA_NA";1,10815056090644;0,330863916168362;1,17007125265025;0,385811579287926;20;6;30;29;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"17";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"remission";"ham-d-17";"clinician";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;30;3;29;19,2;2,3;30;18,4;3,4;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_remission_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA";1,17485144826605;0,391842523093344;1,57553636075842;0,576353978077689;15;3;30;29;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"18";"Carhart-Harris, 2021";"psil";"esc";NA;NA;"remission";"madrs";"clinician";"depression";0;"Post-second dose 1";6;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;30;2;29;27,9;4;30;26,9;5,3;29;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2021;"psilocybin";"escitalopram";"mg 25";"mg 10; mg 20";"psilocybin group";"escitalopram group";2;41,235593220339;0,340508474576271;"dep";NA;"parallel";"double-blind";101056;3429075;"Carhart-Harris2021_remission_madrs_Week6_3.00_clinician_psil_esc_NA_NA";0,955007950884727;0,459878100635296;1,47017584510059;0,737085489720893;9;2;30;29;"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402â€“1411. https://doi.org/10.1056/nejmoa2032994"
"19";"Davis, 2021";"psil";"wl";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-second dose 1";5;1;7;0;0;13;8,2;8,9;11;35,2;9,1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;7;13;34,5;10;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"first dose: mg 20/70 kg; second dose mg 30/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;0,667777777777778;"dep";NA;"crossover";"open-label";101001;3181529;"Davis2021_msd_bdi_Week5_1.00_self-report_psil_wl_NA_NA";2,8993026484422;0,596396246972318;NA;NA;NA;NA;NA;NA;"Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285; Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151â€“158. https://doi.org/10.1177/02698811211073759"
"20";"Davis, 2021";"psil";"wl";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-second dose 2";8;4;28;1;0;13;8,2;7;11;35,9;8,4;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;7;13;34,5;10;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"first dose: mg 20/70 kg; second dose mg 30/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;0,667777777777778;"dep";NA;"crossover";"open-label";101001;3181529;"Davis2021_msd_bdi_Week8_4.00_self-report_psil_wl_NA_NA";3,48779651560761;0,663090832701423;NA;NA;NA;NA;NA;NA;"Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285; Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151â€“158. https://doi.org/10.1177/02698811211073759"
"21";"Davis, 2021";"psil";"wl";NA;NA;"msd";"qids-sr";"self-report";"depression";0;"Post-second dose 1";5;1;7;0;0;13;5,2;4,6;11;31,9;5,6;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,2;3,6;13;17,4;3,6;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"first dose: mg 20/70 kg; second dose mg 30/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;0,667777777777778;"dep";NA;"crossover";"open-label";101001;3181529;"Davis2021_msd_qids-sr_Week5_1.00_self-report_psil_wl_NA_NA";5,07565447275227;0,862303533688809;NA;NA;NA;NA;NA;NA;"Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285; Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151â€“158. https://doi.org/10.1177/02698811211073759"
"22";"Davis, 2021";"psil";"wl";NA;NA;"msd";"qids-sr";"self-report";"depression";0;"Post-second dose 2";8;4;28;1;0;13;5,5;3,6;11;17,7;3,7;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,2;3,6;13;17,4;3,6;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"first dose: mg 20/70 kg; second dose mg 30/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;0,667777777777778;"dep";NA;"crossover";"open-label";101001;3181529;"Davis2021_msd_qids-sr_Week8_4.00_self-report_psil_wl_NA_NA";3,23093088729085;0,63334117548284;NA;NA;NA;NA;NA;NA;"Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285; Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151â€“158. https://doi.org/10.1177/02698811211073759"
"23";"Davis, 2021";"psil";"wl";NA;NA;"msd";"grid-ham-d";"clinician";"depression";1;"Post-second dose 1";5;1;7;0;0;13;8;7,1;11;23,8;5,4;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,9;3,6;13;22,5;4,4;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"first dose: mg 20/70 kg; second dose mg 30/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;0,667777777777778;"dep";NA;"crossover";"open-label";101001;3181529;"Davis2021_msd_grid-ham-d_Week5_1.00_clinician_psil_wl_NA_NA";2,3897279858468;0,543559686244671;NA;NA;NA;NA;NA;NA;"Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285; Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151â€“158. https://doi.org/10.1177/02698811211073759"
"24";"Davis, 2021";"psil";"wl";NA;NA;"msd";"grid-ham-d";"clinician";"depression";1;"Post-second dose 2";8;4;28;1;0;13;8,5;5,7;11;23,5;6;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,9;3,6;13;22,5;4,4;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"first dose: mg 20/70 kg; second dose mg 30/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;0,667777777777778;"dep";NA;"crossover";"open-label";101001;3181529;"Davis2021_msd_grid-ham-d_Week8_4.00_clinician_psil_wl_NA_NA";2,48065716535765;0,552588609503246;NA;NA;NA;NA;NA;NA;"Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285; Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151â€“158. https://doi.org/10.1177/02698811211073759"
"25";"Davis, 2021";"psil";"wl";NA;NA;"msd";"phq-9";"self-report";"depression";0;"Post-second dose 2";8;4;28;1;0;13;4,8;2,9;11;18,8;4,3;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,5;3,1;13;17,9;3,3;11;"Low";"Some concerns";"Some concerns";"Low";"Low";"Some concerns";2021;"psilocybin";"waitlist";"first dose: mg 20/70 kg; second dose mg 30/70kg";NA;"immediate treatment group";"delayed treatment group";2;39,8666666666667;0,667777777777778;"dep";NA;"crossover";"open-label";101001;3181529;"Davis2021_msd_phq-9_Week8_4.00_self-report_psil_wl_NA_NA";3,75018853776688;0,694357648017136;NA;NA;NA;NA;NA;NA;"Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285; Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151â€“158. https://doi.org/10.1177/02698811211073759"
"26";"Goodwin, 2022";"psil";"psil";25;10;"change";"qids-sr";"self-report";"depression";0;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;79;-6,3;5,89523099107666;75;-5,2;5,96497089341323;NA;NA;NA;NA;16,1;4,14;79;16,3;4,16;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_10mg";0,18460291306013;0,161565177688826;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"27";"Goodwin, 2022";"psil";"psil";25;1;"change";"qids-sr";"self-report";"depression";0;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;79;-6,3;5,89523099107666;79;-3,6;6,12197064457961;NA;NA;NA;NA;16,1;4,14;79;15,8;3,96;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_1mg";0,44711245099768;0,161106231491561;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"28";"Goodwin, 2022";"psil";"psil";10;1;"change";"qids-sr";"self-report";"depression";0;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;75;-5,2;5,96497089341323;79;-3,6;6,12197064457961;NA;NA;NA;NA;16,3;4,16;75;15,8;3,96;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_10mg_1mg";0,263327851165626;0,161922629984635;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"29";"Goodwin, 2022";"psil";"psil";25;10;"change";"qids-sr";"self-report";"depression";0;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;79;-6,5;29,2494153018804;75;-5,5;7,06959513293419;NA;NA;NA;NA;16,1;4,14;79;16,3;4,16;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_10mg";0,0462266292804944;0,161240715280361;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"30";"Goodwin, 2022";"psil";"psil";25;1;"change";"qids-sr";"self-report";"depression";0;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;79;-6,5;29,2494153018804;79;-5;7,02892925859141;NA;NA;NA;NA;16,1;4,14;79;15,8;3,96;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_1mg";0,0701780687826577;0,159160900372791;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"31";"Goodwin, 2022";"psil";"psil";10;1;"change";"qids-sr";"self-report";"depression";0;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;75;-5,5;7,06959513293419;79;-5;7,02892925859141;NA;NA;NA;NA;16,3;4,16;75;15,8;3,96;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_10mg_1mg";0,0705839158493311;0,161269643391451;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"32";"Goodwin, 2022";"psil";"psil";25;10;"change";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,0523916298799;75;-11,986;12,2369389554741;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg";0,249121145931711;0,161848897621857;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"33";"Goodwin, 2022";"psil";"psil";25;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,0523916298799;79;-9,078;12,0523916298799;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg";0,491135546139263;0,161515313598675;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"34";"Goodwin, 2022";"psil";"psil";10;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;75;-11,986;12,2369389554741;79;-9,078;12,0523916298799;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg";0,238304043542571;0,161795477652513;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"35";"Goodwin, 2022";"psil";"psil";25;10;"change";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,1280194104791;75;-8,796;11,7779454914684;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg";0,369114770371633;0,162598654898194;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"36";"Goodwin, 2022";"psil";"psil";25;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,1280194104791;79;-6,887;11,5902055201795;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg";0,539222490615264;0,162004663914633;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"37";"Goodwin, 2022";"psil";"psil";10;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;75;-8,796;11,7779454914684;79;-6,887;11,5902055201795;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg";0,162606401269336;0,16148765578732;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"38";"Goodwin, 2022";"psil";"psil";25;10;"change";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;79;-12;12,0172016356563;75;-7,9;11,9299417868265;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg";0,340693510443015;0,16239510909666;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"39";"Goodwin, 2022";"psil";"psil";25;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;79;-12;12,0172016356563;79;-5,4;12,2439412891592;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg";0,541436278652384;0,162028254630371;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"40";"Goodwin, 2022";"psil";"psil";10;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;75;-7,9;11,9299417868265;79;-5,4;12,2439412891592;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg";0,205724883723145;0,161648820099789;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"41";"Goodwin, 2022";"psil";"psil";25;10;"change";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;79;-11,53;13,4478381533985;75;-5,991;13,5879385853778;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg";0,407778343065248;0,162901252285212;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"42";"Goodwin, 2022";"psil";"psil";25;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;79;-11,53;13,4478381533985;79;-6,261;12,9856520436981;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg";0,396680590448086;0,160683685359775;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"43";"Goodwin, 2022";"psil";"psil";10;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;75;-5,991;13,5879385853778;79;-6,261;12,9856520436981;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg";-0,0202273645515336;0,161223146003312;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"44";"Goodwin, 2022";"psil";"psil";25;10;"change";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,3722103727993;75;-6,109;14,4972652593515;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg";0,222683124641113;0,161722489932522;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"45";"Goodwin, 2022";"psil";"psil";25;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,3722103727993;79;-5,322;14,3810985672166;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg";0,278065826659824;0,159885943110615;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"46";"Goodwin, 2022";"psil";"psil";10;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;75;-6,109;14,4972652593515;79;-5,322;14,3810985672166;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg";0,0542403965640219;0,161248901762607;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"47";"Goodwin, 2022";"psil";"psil";25;10;"change";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,3810985672166;75;-5,651;14,0469320493836;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg";0,26906891465809;0,161953575769648;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"48";"Goodwin, 2022";"psil";"psil";25;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,3810985672166;79;-6;14,843284676917;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg";0,238070400496671;0,159679538002117;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"49";"Goodwin, 2022";"psil";"psil";10;1;"change";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;75;-5,651;14,0469320493836;79;-6;14,843284676917;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg";-0,0240144904164293;0,161224849872201;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"50";"Goodwin, 2022";"psil";"psil";25;10;"response";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;24;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg";0,483058754617036;0,184601397856223;0,507656049004712;0,19870739617527;42;24;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"51";"Goodwin, 2022";"psil";"psil";25;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;18;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg";0,739203166461471;0,193189884520747;0,847297860387203;0,232483598709408;42;18;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"52";"Goodwin, 2022";"psil";"psil";10;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24;75;18;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg";0,256050130736952;0,201233919986895;0,339641811382492;0,266890728652735;24;18;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"53";"Goodwin, 2022";"psil";"psil";25;10;"response";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;17;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg";0,547719742802428;0,196758469095511;0,670174978502487;0,247797087960611;35;17;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"54";"Goodwin, 2022";"psil";"psil";25;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;12;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg";0,818042457672835;0,213213509731684;1,07044141170141;0,294258910160014;35;12;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"55";"Goodwin, 2022";"psil";"psil";10;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;75;12;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg";0,270218378265294;0,230191279338547;0,400266433198927;0,340830311978943;17;12;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"56";"Goodwin, 2022";"psil";"psil";25;10;"response";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg";0,508604968699563;0,207979479793817;0,676278761440504;0,282700846952793;29;14;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"57";"Goodwin, 2022";"psil";"psil";25;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg";0,543518002322607;0,207240964352298;0,728238500371216;0,283892364027387;29;14;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"58";"Goodwin, 2022";"psil";"psil";10;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;75;14;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg";0,0348437110314746;0,230396909206025;0,0519597389307112;0,341856083280243;14;14;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"59";"Goodwin, 2022";"psil";"psil";25;10;"response";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;11;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg";0,575371767937793;0,223178286826114;0,8082415262924;0,321526154751359;26;11;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"60";"Goodwin, 2022";"psil";"psil";25;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;16;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg";0,361219886716389;0,203097531606742;0,485507815781701;0,275036511694967;26;16;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"61";"Goodwin, 2022";"psil";"psil";10;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;75;16;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg";-0,214197952738018;0,237075981004254;-0,3227337105107;0,356955921267117;11;16;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"62";"Goodwin, 2022";"psil";"psil";25;10;"response";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg";0,316227935645098;0,224733656397081;0,45886588483528;0,327630542153656;20;12;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"63";"Goodwin, 2022";"psil";"psil";25;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg";0,350043490526369;0,224091872823937;0,510825623765991;0,328659212007104;20;12;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"64";"Goodwin, 2022";"psil";"psil";10;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;12;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg";0,0337709088496372;0,244994243823549;0,051959738930711;0,375066801363746;12;12;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"65";"Goodwin, 2022";"psil";"psil";25;10;"response";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;12;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg";0,51899736264532;0,218131110395555;0,721230149302771;0,309521098817895;26;12;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"66";"Goodwin, 2022";"psil";"psil";25;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;13;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg";0,500670535974563;0,213104169598532;0,693147180559945;0,300113577980759;26;13;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"67";"Goodwin, 2022";"psil";"psil";10;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;13;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg";-0,0183906843147135;0,241127423028606;-0,0280829687428252;0,366421682048123;12;13;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"68";"Goodwin, 2022";"psil";"psil";25;10;"response";"madrs";"clinician";"depression";1;"Post-first dose 7";3;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;3;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_10mg";0,991606097434806;0,359674074446653;1,62201669464096;0,608146176631818;16;3;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"69";"Goodwin, 2022";"psil";"psil";25;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 7";3;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;6;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_1mg";0,618988773944865;0,280440753604151;0,980829253011726;0,451497741932852;16;6;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"70";"Goodwin, 2022";"psil";"psil";10;1;"response";"madrs";"clinician";"depression";1;"Post-first dose 7";3;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;75;6;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_10mg_1mg";-0,372696271943864;0,400458956333702;-0,641187441629234;0,688482707712086;3;6;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"71";"Goodwin, 2022";"psil";"psil";25;10;"remission";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;16;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg";0,446742427362801;0,201209101839793;0,576648920491663;0,264275939411628;30;16;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"72";"Goodwin, 2022";"psil";"psil";25;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;15;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg";0,526842263065698;0,203344838513193;0,693147180559945;0,273282901594296;30;15;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"73";"Goodwin, 2022";"psil";"psil";10;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;75;15;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg";0,0800326400058482;0,221728017482283;0,116498260068282;0,321208819127421;16;15;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"74";"Goodwin, 2022";"psil";"psil";25;10;"remission";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;8;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg";0,743436846825519;0,245600712471635;1,08747454425765;0,372838354811526;25;8;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"75";"Goodwin, 2022";"psil";"psil";25;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;9;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg";0,70294054932581;0,236439338957101;1,02165124753198;0,354675422625967;25;9;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"76";"Goodwin, 2022";"psil";"psil";10;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;75;9;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg";-0,0405859535191799;0,283986403909221;-0,0658232967256723;0,458387990603677;8;9;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"77";"Goodwin, 2022";"psil";"psil";25;10;"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;7;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg";0,759125400183882;0,257947947756852;1,13762432794313;0,400429572515909;23;7;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"78";"Goodwin, 2022";"psil";"psil";25;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;6;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg";0,882730082250152;0,271050185749346;1,34373474670109;0,429916819675655;23;6;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"79";"Goodwin, 2022";"psil";"psil";10;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;6;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg";0,123492094927119;0,320496322472041;0,206110418757969;0,53247746275535;7;6;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"80";"Goodwin, 2022";"psil";"psil";25;10;"remission";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;7;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg";0,653822118763376;0,261234604859298;0,997862385567967;0,408491837954822;20;7;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"81";"Goodwin, 2022";"psil";"psil";25;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;10;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg";0,466217226903541;0,234844046305309;0,693147180559945;0,353105571046107;20;10;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"82";"Goodwin, 2022";"psil";"psil";10;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;10;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg";-0,187664355182606;0,28756745397276;-0,304715205008021;0,465688288102362;7;10;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"83";"Goodwin, 2022";"psil";"psil";25;10;"remission";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg";0,34116816345177;0,249402839658612;0,523404405972851;0,38421289662071;16;9;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"84";"Goodwin, 2022";"psil";"psil";25;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg";0,373495936789863;0,248874676341758;0,575364144903562;0,385090450952641;16;9;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"85";"Goodwin, 2022";"psil";"psil";10;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;75;9;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg";0,0322801360819781;0,276577838141005;0,051959738930711;0,442979300916857;9;9;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"86";"Goodwin, 2022";"psil";"psil";25;10;"remission";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;5;75;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg";0,890459383732184;0,291290666364917;1,38312478635861;0,47077328560318;21;5;79;75;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"87";"Goodwin, 2022";"psil";"psil";25;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;9;79;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg";0,56806969819056;0,24048132985056;0,847297860387203;0,365258405836137;21;9;79;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"88";"Goodwin, 2022";"psil";"psil";10;1;"remission";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;75;9;79;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg";-0,322462139560631;0,321327108955673;-0,535826925971408;0,533965869629957;5;9;75;79;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"89";"Goodwin, 2022";"psil";"psil";25;10;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;79;16,874;10,952204379562;75;21,014;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg";0,384358280855718;0,162714427016056;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"90";"Goodwin, 2022";"psil";"psil";25;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;79;16,874;10,952204379562;79;23,622;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg";0,626939817845911;0,163010313427856;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"91";"Goodwin, 2022";"psil";"psil";10;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;75;21,014;10,952204379562;79;23,622;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg";0,24241682828647;0,161815511228902;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"92";"Goodwin, 2022";"psil";"psil";25;10;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;79;18,857;10,952204379562;75;24,204;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg";0,496416359356407;0,163705906101791;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"93";"Goodwin, 2022";"psil";"psil";25;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;79;18,857;10,952204379562;79;25,813;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg";0,646264578087753;0,163251277296014;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"94";"Goodwin, 2022";"psil";"psil";10;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";1;1;7;0;NA;75;24,204;10,952204379562;79;25,813;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg";0,149558541684406;0,161446297506041;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"95";"Goodwin, 2022";"psil";"psil";25;10;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;79;19,9;10,952204379562;75;25,1;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg";0,482768855181096;0,163572014244934;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"96";"Goodwin, 2022";"psil";"psil";25;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;79;19,9;10,952204379562;79;27,3;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg";0,687515508603992;0,163788831906761;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"97";"Goodwin, 2022";"psil";"psil";10;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 3";3;3;21;1;NA;75;25,1;10,952204379562;79;27,3;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg";0,204492723247789;0,161643693390267;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"98";"Goodwin, 2022";"psil";"psil";25;10;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;79;20,37;10,952204379562;75;27,009;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg";0,616365851836018;0,16503729398211;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"99";"Goodwin, 2022";"psil";"psil";25;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;79;20,37;10,952204379562;79;26,439;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg";0,563855624556437;0,162272405190914;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"100";"Goodwin, 2022";"psil";"psil";10;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 4";6;6;42;0;NA;75;27,009;10,952204379562;79;26,439;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg";-0,052982205568745;0,161247530057391;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"101";"Goodwin, 2022";"psil";"psil";25;10;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;79;22,561;10,952204379562;75;26,891;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg";0,40199791210272;0,162854134329552;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"102";"Goodwin, 2022";"psil";"psil";25;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;79;22,561;10,952204379562;79;27,378;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg";0,447535433100734;0,161109984092392;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"103";"Goodwin, 2022";"psil";"psil";10;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 5";9;9;63;0;NA;75;26,891;10,952204379562;79;27,378;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg";0,0452672528280338;0,161239822734812;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"104";"Goodwin, 2022";"psil";"psil";25;10;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;79;22,404;10,952204379562;75;27,349;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;33;6,31;75;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 10";"25-mg group";"10-mg group";1;40,3948051948052;0,55512987012987;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg";0,459094613244331;0,163348361190656;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"105";"Goodwin, 2022";"psil";"psil";25;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;79;22,404;10,952204379562;79;26,7;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,9;5,41;79;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 25";"mg 1";"25-mg group";"1-mg group";1;39,45;0,51;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg";0,399130624994967;0,160703070097083;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"106";"Goodwin, 2022";"psil";"psil";10;1;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 6";12;12;84;0;NA;75;27,349;10,952204379562;79;26,7;10,465390625;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;6,31;75;32,7;6,24;79;"Low";"Low";"Low";"Low";"Low";"Low";2022;"psilocybin";"psilocybin";"mg 10";"mg 1";"10-mg group";"1-mg group";1;39,6253246753247;0,503831168831169;"trd";NA;"parallel";"double-blind";101056;3775200;"Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg";-0,0603253533580975;0,161255989845426;NA;NA;NA;NA;NA;NA;"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., â€¦ Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637â€“1648. https://doi.org/10.1056/nejmoa2206443; Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., PÃ¡lenÃ­Ä<8d>ek, T., Redjep, O., Repantis, D., â€¦ Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120â€“127. https://doi.org/10.1016/j.jad.2023.01.108"
"107";"Griffiths, 2016";"psil";"psil";22;1;"msd";"bdi";"self-report";"depression";0;"Post-first dose 1";5;5;35;1;0;26;7;7,08763712389397;25;12,92;7,9;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,77;8,20942141688438;26;18,4;5,45;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_bdi_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg";0,777548803674066;0,290818652815185;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"108";"Griffiths, 2016";"psil";"psil";22;1;"msd";"bdi";"self-report";"depression";0;"Post-second dose 1";5;5;35;0;1;25;5,8;7,05;24;8,17;6,07473456210228;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,77;8,20942141688438;26;18,4;5,45;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_bdi_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg";0,353823395756413;0,288073118615127;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"109";"Griffiths, 2016";"psil";"psil";22;1;"msd";"bdi";"self-report";"depression";0;"Follow-up 1";6;26,09;183;0;1;24;6,17;6,17271415181361;22;8;7,03562363973514;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,77;8,20942141688438;26;18,4;5,45;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_bdi_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg";0,272575291467599;0,296575805493764;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"110";"Griffiths, 2016";"psil";"psil";22;1;"msd";"grid-ham-d";"clinician";"depression";1;"Post-first dose 1";5;5;35;1;0;25;6,64;5,2;25;14,8;7,25;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg";1,27311104197224;0,311013705206831;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"111";"Griffiths, 2016";"psil";"psil";22;1;"msd";"grid-ham-d";"clinician";"depression";1;"Post-second dose 1";5;5;35;0;1;25;6,52;7,2;24;6,5;4,21312235758707;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg";-0,00331890655475998;0,285774006447645;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"112";"Griffiths, 2016";"psil";"psil";22;1;"msd";"grid-ham-d";"clinician";"depression";1;"Follow-up 1";6;26,09;183;0;1;24;6,23;6,36867333123626;22;6,95;5,81611554218105;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg";0,115796985535777;0,295418499944029;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"113";"Griffiths, 2016";"psil";"psil";22;1;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 1";5;5;35;1;0;26;3,92;3,77327444005866;25;6,04;3,95;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,81;3,51832346437902;26;9,48;3,55;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_hads-d_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg";0,540654890825001;0,285337615889013;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"114";"Griffiths, 2016";"psil";"psil";22;1;"msd";"hads-d";"self-report";"depression";0;"Post-second dose 1";5;5;35;0;1;25;4,28;4,45;24;4,57;3,57625502446344;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,81;3,51832346437902;26;9,48;3,55;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_hads-d_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg";0,0705246893873731;0,285865505950152;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"115";"Griffiths, 2016";"psil";"psil";22;1;"msd";"hads-d";"self-report";"depression";0;"Follow-up 1";6;26,09;183;0;1;24;3,46;3,2333264604738;22;4,64;3,37709934707287;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,81;3,51832346437902;26;9,48;3,55;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_msd_hads-d_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg";0,351155795867404;0,297504127606758;NA;NA;NA;NA;NA;NA;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"116";"Griffiths, 2016";"psil";"psil";22;1;"response";"grid-ham-d";"clinician";"depression";1;"Post-first dose 1";5;5;35;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;25;8;25;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_response_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg";1,73443550611936;0,470184256190578;1,05605267424931;0,297452955725044;23;8;25;25;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"117";"Griffiths, 2016";"psil";"psil";22;1;"response";"grid-ham-d";"clinician";"depression";1;"Post-second dose 1";5;5;35;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;25;18;24;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_response_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg";0,303582637310363;0,397508236769202;0,113328685307003;0,146655843756519;21;18;25;24;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"118";"Griffiths, 2016";"psil";"psil";22;1;"response";"grid-ham-d";"clinician";"depression";1;"Follow-up 1";6;26,09;183;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19;24;17;22;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_response_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg";0,0602706738642289;0,394288867299855;0,0242142581205945;0,155993257027094;19;17;24;22;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"119";"Griffiths, 2016";"psil";"psil";22;1;"remission";"grid-ham-d";"clinician";"depression";1;"Post-first dose 1";5;5;35;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;25;4;25;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_remission_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg";1,11990289316815;0,375667318726251;1,32175583998232;0,486483983977547;15;4;25;25;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"120";"Griffiths, 2016";"psil";"psil";22;1;"remission";"grid-ham-d";"clinician";"depression";1;"Post-second dose 1";5;5;35;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;25;14;24;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_remission_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg";0,226378357172157;0,328608718760945;0,153334019920702;0,220421038409834;17;14;25;24;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"121";"Griffiths, 2016";"psil";"psil";22;1;"remission";"grid-ham-d";"clinician";"depression";1;"Follow-up 1";6;26,09;183;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;24;13;22;22,84;4,946048928185;26;22,32;4,4;25;"Low";"Low";"Low";"Some concerns";"High";"High";2016;"psilocybin";"psilocybin";"mg 22/kg";"mg 1/kg";"High-Dose-1st Group";"Low-Dose-1st Group";1;56,3071428571429;0,490357142857143;"cancer";NA;"crossover";"double-blind";101177;465595;"Griffiths2016_remission_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg";0,281547874811647;0,344178896486629;0,18125260960505;0,220511664574982;17;13;24;22;"Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181â€“1197. https://doi.org/10.1177/0269881116675513"
"122";"Grob, 2011";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Pre-first dose 1";1;-0,14;-1;0;1;12;16,09;12,7097888259404;12;14,369;13,6485603636428;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Some concerns";"Low";"Some concerns";"High";"High";2011;"psilocybin";"niacin";"mg 0.2/kg";"mg 250";"psilocybin";"niacin placebo";1;NA;NA;"cancer";NA;"crossover";"double-blind";101001;302744;"Grob2011_msd_bdi_1daybeforeexperimentalsession_-0.14_self-report_psil_ncn_NA_NA";-0,126001994614439;0,408682608848014;NA;NA;NA;NA;NA;NA;"Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry, 68(1), 71. https://doi.org/10.1001/archgenpsychiatry.2010.116"
"123";"Grob, 2011";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 1";1;0,14;1;0;1;12;11,442;10,0424305822844;12;13,208;11,767553186623;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Some concerns";"Low";"Some concerns";"High";"High";2011;"psilocybin";"niacin";"mg 0.2/kg";"mg 250";"psilocybin";"niacin placebo";1;NA;NA;"cancer";NA;"crossover";"double-blind";101001;302744;"Grob2011_msd_bdi_1dayafterexperimentalsession_0.14_self-report_psil_ncn_NA_NA";0,155873053599128;0,408912757018787;NA;NA;NA;NA;NA;NA;"Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry, 68(1), 71. https://doi.org/10.1001/archgenpsychiatry.2010.116"
"124";"Grob, 2011";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 2";2;2;14;1;1;12;10,054;9,25607951564808;12;13,27;10,9812021199867;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;"Low";"Some concerns";"Low";"Some concerns";"High";"High";2011;"psilocybin";"niacin";"mg 0.2/kg";"mg 250";"psilocybin";"niacin placebo";1;NA;NA;"cancer";NA;"crossover";"double-blind";101001;302744;"Grob2011_msd_bdi_2weeksafterexperimentalsession_2.00_self-report_psil_ncn_NA_NA";0,30576069806098;0,41079918756803;NA;NA;NA;NA;NA;NA;"Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry, 68(1), 71. https://doi.org/10.1001/archgenpsychiatry.2010.116"
"125";"Krempien, 2023";"psil-d";"psil-d";16;12;"msd";"madrs";"clinician";"depression";1;"Post-first dose 4";21;3;21;1;NA;9;16,556;6,146;15;15,867;8,684;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,035;9;32,611;3,664;18;NA;NA;NA;NA;NA;NA;2023;"CYB003 deuterated psilocin";"CYB003 deuterated psilocin";"mg 16";"mg 12";"16 mg group";"12 mg group";1;NA;NA;"dep";NA;"parallel";"double-blind";101038;5385783;"Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_psil-d_16mg_12mg";-0,0846736545215689;0,421826984238059;NA;NA;NA;NA;NA;NA;"Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S. A., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). P226. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of CYB003, a deuterated psilocybin analog in patients with major depressive disorder, Neuropsychopharmacology, 48(S1), 63â€“210. https://doi.org/10.1038/s41386-023-01755-5"
"126";"Krempien, 2023";"psil-d";"pcb";16;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 4";21;3;21;1;NA;9;16,556;6,146;9;29;5,315;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,035;9;31,556;4,927;9;NA;NA;NA;NA;NA;NA;2023;"CYB003 deuterated psilocin";"placebo";"mg 16";NA;"16 mg group";"placebo";1;NA;NA;"dep";NA;"parallel";"double-blind";101038;5385783;"Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_16mg_NA";2,06271669538169;0,593738559711083;NA;NA;NA;NA;NA;NA;"Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S. A., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). P226. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of CYB003, a deuterated psilocybin analog in patients with major depressive disorder, Neuropsychopharmacology, 48(S1), 63â€“210. https://doi.org/10.1038/s41386-023-01755-5"
"127";"Krempien, 2023";"psil-d";"pcb";12;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 4";21;3;21;1;NA;15;15,867;8,684;9;29;5,315;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;32,611;3,664;18;31,556;4,927;9;NA;NA;NA;NA;NA;NA;2023;"CYB003 deuterated psilocin";"placebo";"mg 12";NA;"12 mg group";"placebo";1;NA;NA;"dep";NA;"parallel";"double-blind";101038;5385783;"Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_12mg_NA";1,66123853816433;0,489338185039199;NA;NA;NA;NA;NA;NA;"Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S. A., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). P226. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of CYB003, a deuterated psilocybin analog in patients with major depressive disorder, Neuropsychopharmacology, 48(S1), 63â€“210. https://doi.org/10.1038/s41386-023-01755-5"
"128";"Raison, 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;NA;NA;NA;NA;NA;NA;51;-2,7;5,10102030610204;53;-2,7;5,20007849234323;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_change_madrs_Day2_0.29_clinician_psil_ncn_NA_NA";0;0,196152409277982;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"129";"Raison, 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 2";8;1,14;8;0;NA;NA;NA;NA;NA;NA;NA;51;-17,8;11,8416542820226;53;-5,8;12,0716107857968;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_change_madrs_Day8_1.14_clinician_psil_ncn_NA_NA";0,995995497988749;0,208125264900041;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"130";"Raison, 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 3";15;2,14;15;0;NA;NA;NA;NA;NA;NA;NA;51;-18;12,0238335786691;53;-6,9;12,6287620528336;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_change_madrs_Day15_2.14_clinician_psil_ncn_NA_NA";0,89317763251305;0,20583574904796;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"131";"Raison, 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 4";29;4,14;29;0;NA;NA;NA;NA;NA;NA;NA;51;-19,2;12,3881921719621;53;-5,5;13,0001962308581;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_change_madrs_Day29_4.14_clinician_psil_ncn_NA_NA";1,07046182341652;0,209921339689726;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"132";"Raison, 2023";"psil";"ncn";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 5";43;6,14;43;1;NA;NA;NA;NA;NA;NA;NA;51;-19,1;13,1169093585481;53;-6,8;13,7430645869071;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_change_madrs_Day43_6.14_clinician_psil_ncn_NA_NA";0,908448235718669;0,206161577613683;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"133";"Raison, 2023";"psil";"ncn";NA;NA;"change";"smdds";"self-report";"depression";0;"Post-first dose 2";8;1,14;8;0;NA;NA;NA;NA;NA;NA;NA;51;-21,1;14,3921644350736;48;-9,6;14,3159301441917;NA;NA;NA;NA;43,2;8,7;51;44,3;5,9;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_change_smdds_Day8_1.14_self-report_psil_ncn_NA_NA";0,794889080131949;0,209003320149336;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"134";"Raison, 2023";"psil";"ncn";NA;NA;"change";"smdds";"self-report";"depression";0;"Post-first dose 5";43;6,14;43;1;NA;NA;NA;NA;NA;NA;NA;50;-21,8;14,7915194023717;42;-10,8;14,3832765500379;NA;NA;NA;NA;43,2;8,7;51;44,3;5,9;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_change_smdds_Day43_6.14_self-report_psil_ncn_NA_NA";0,746772780986188;0,216544760098465;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"135";"Raison, 2023";"psil";"ncn";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 5";43;6,14;43;1;NA;50;16,1;13;44;27,3;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_msd_madrs_Day43_6.14_clinician_psil_ncn_NA_NA";0,869971940431115;0,216378625859585;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"136";"Raison, 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 2";8;1,14;8;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27;51;5;50;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_response_madrs_Day8_1.14_clinician_psil_ncn_NA_NA";1,26663694011237;0,302440924827385;1,66659632627405;0,444330050637791;27;5;51;50;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"137";"Raison, 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 3";15;2,14;15;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;50;8;45;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_response_madrs_Day15_2.14_clinician_psil_ncn_NA_NA";0,837519570771861;0,26557062911055;1,03407376753054;0,350396600693811;25;8;50;45;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"138";"Raison, 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 4";29;4,14;29;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;49;7;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_response_madrs_Day29_4.14_clinician_psil_ncn_NA_NA";0,977415960975367;0,276668227108227;1,2045557247738;0,371730070516366;26;7;49;44;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"139";"Raison, 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 5";43;6,14;43;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;50;9;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_response_madrs_Day43_6.14_clinician_psil_ncn_NA_NA";0,919151592975676;0,259642749420353;1,04223788114037;0,320728229198067;29;9;50;44;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"140";"Raison, 2023";"psil";"ncn";NA;NA;"response";"madrs";"clinician";"depression";1;"Follow-up 1";8;6,14;43;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;48;5;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_response_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA";0,939077329599338;0,307637231231115;1,29928298413026;0,454356021132541;20;5;48;44;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"141";"Raison, 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 2";8;1,14;8;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;51;4;50;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_remission_madrs_Day8_1.14_clinician_psil_ncn_NA_NA";1,00466752808607;0,329691782803155;1,48427476948009;0,515701185201567;18;4;51;50;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"142";"Raison, 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";15;2,14;15;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;50;6;45;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_remission_madrs_Day15_2.14_clinician_psil_ncn_NA_NA";0,801896794326249;0,289456084639812;1,09861228866811;0,417665469538056;20;6;50;45;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"143";"Raison, 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 4";29;4,14;29;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;49;5;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_remission_madrs_Day29_4.14_clinician_psil_ncn_NA_NA";0,825904329377777;0,308672621340806;1,1733031812697;0,460890572221842;18;5;49;44;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"144";"Raison, 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 5";43;6,14;43;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;50;5;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_remission_madrs_Day43_6.14_clinician_psil_ncn_NA_NA";0,991367547103598;0,305383387785473;1,35377116941433;0,450252454437811;22;5;50;44;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"145";"Raison, 2023";"psil";"ncn";NA;NA;"remission";"madrs";"clinician";"depression";1;"Follow-up 1";8;6,14;43;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;48;4;44;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_remission_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA";0,658238046496866;0,342583864748047;1,01160091167848;0,538305421923955;12;4;48;44;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"146";"Raison, 2023";"psil";"ncn";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;51;32,8;13;53;32,3;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_imsd_madrs_Day2_0.29_clinician_psil_ncn_NA_NA";-0,0389341123321014;0,196171262205403;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"147";"Raison, 2023";"psil";"ncn";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";8;1,14;8;0;NA;51;17,7;13;53;29,2;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_imsd_madrs_Day8_1.14_clinician_psil_ncn_NA_NA";0,895484583638332;0,205884651101164;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"148";"Raison, 2023";"psil";"ncn";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 3";15;2,14;15;0;NA;51;17,5;13;53;28,1;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_imsd_madrs_Day15_2.14_clinician_psil_ncn_NA_NA";0,82540318144055;0,204450551529181;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"149";"Raison, 2023";"psil";"ncn";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 4";29;4,14;29;0;NA;51;16,3;13;53;29,5;12,5;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,5;5,7;51;35;4,5;53;"Low";"Low";"Low";"Low";"Low";"Low";2023;"psilocybin";"niacin";"mg 25";"mg 100";"psilocybin";"niacin";1;41,1134615384615;0,500576923076923;"dep";NA;"parallel";"double-blind";101001;3866174;"Raison2023_imsd_madrs_Day29_4.14_clinician_psil_ncn_NA_NA";1,02786056556748;0,208879863202166;NA;NA;NA;NA;NA;NA;"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., Oâ€™Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., â€¦ Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA, 330(9), 843. https://doi.org/10.1001/jama.2023.14530; Error in Byline. (2024). JAMA, 331(8), 710. https://doi.org/10.1001/jama.2024.0828"
"150";"Rieser, 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Flexible Timepoint 1";-14;-2;-14;0;NA;18;12,72;8,37;19;12,21;7,75;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"mg 25";"100% mannitol";"psilocybin";"placebo";1;37,2675;0,377975;"aud";NA;"parallel";"double-blind";101016;4141501;"Rieser2025_msd_bdi_Day-14_-2.00_self-report_psil_pcb_NA_NA";-0,0619320308487031;0,329000423326536;NA;NA;NA;NA;NA;NA;"Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., ThÃ©venaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine, 82, 103149. https://doi.org/10.1016/j.eclinm.2025.103149"
"151";"Rieser, 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 1";1;0,14;1;0;NA;18;6,11;5,61;19;8,61;10,8;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"mg 25";"100% mannitol";"psilocybin";"placebo";1;37,2675;0,377975;"aud";NA;"parallel";"double-blind";101016;4141501;"Rieser2025_msd_bdi_Day1_0.14_self-report_psil_pcb_NA_NA";0,281932583311054;0,33061938896167;NA;NA;NA;NA;NA;NA;"Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., ThÃ©venaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine, 82, 103149. https://doi.org/10.1016/j.eclinm.2025.103149"
"152";"Rieser, 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 2";14;2;14;0;NA;18;7,17;7,13;18;10,79;10,97;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"mg 25";"100% mannitol";"psilocybin";"placebo";1;37,2675;0,377975;"aud";NA;"parallel";"double-blind";101016;4141501;"Rieser2025_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA";0,382595634956989;0,336507979084192;NA;NA;NA;NA;NA;NA;"Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., ThÃ©venaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine, 82, 103149. https://doi.org/10.1016/j.eclinm.2025.103149"
"153";"Rieser, 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 3";30;4,29;30;1;NA;18;7,17;7,13;19;10,79;10,97;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"mg 25";"100% mannitol";"psilocybin";"placebo";1;37,2675;0,377975;"aud";NA;"parallel";"double-blind";101016;4141501;"Rieser2025_msd_bdi_Day30_4.29_self-report_psil_pcb_NA_NA";0,380644306000238;0,332012714527199;NA;NA;NA;NA;NA;NA;"Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., ThÃ©venaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine, 82, 103149. https://doi.org/10.1016/j.eclinm.2025.103149"
"154";"Rieser, 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 4";96;13,71;96;0;NA;17;7,76;7,97;18;14;12,77;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"mg 25";"100% mannitol";"psilocybin";"placebo";1;37,2675;0,377975;"aud";NA;"parallel";"double-blind";101016;4141501;"Rieser2025_msd_bdi_Day96_13.71_self-report_psil_pcb_NA_NA";0,569039433802074;0,345288659722553;NA;NA;NA;NA;NA;NA;"Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., ThÃ©venaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine, 82, 103149. https://doi.org/10.1016/j.eclinm.2025.103149"
"155";"Rieser, 2025";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 5";190;27,14;190;0;NA;17;9,47;10,26;17;11,41;9,68;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,06;8,99;18;11,05;8,02;19;"Low";"Low";"Some concerns";"Some concerns";"Low";"Some concerns";2025;"psilocybin";"mannitol";"mg 25";"100% mannitol";"psilocybin";"placebo";1;37,2675;0,377975;"aud";NA;"parallel";"double-blind";101016;4141501;"Rieser2025_msd_bdi_Day190_27.14_self-report_psil_pcb_NA_NA";0,189906964495615;0,343807205481078;NA;NA;NA;NA;NA;NA;"Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., ThÃ©venaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine, 82, 103149. https://doi.org/10.1016/j.eclinm.2025.103149"
"156";"Rosenblat, 2024";"psil";"wl";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 1";1;0,14;1;0;0;NA;NA;NA;NA;NA;NA;16;-13,277;6,3;14;-1,064;6,20740960465797;NA;NA;NA;NA;33;3,9;16;27,6;6,6;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"mg 25";NA;"immediate group";"delayed group";1;44,1266666666667;0,391333333333333;"trd";NA;"crossover";"open-label";101016;5029466;"Rosenblat2024_change_madrs_Day1_0.14_clinician_psil_wl_NA_NA";1,8990847527257;0,444323125248803;NA;NA;NA;NA;NA;NA;"Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., â€¦ McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005"
"157";"Rosenblat, 2024";"psil";"wl";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 2";7;1;7;0;0;NA;NA;NA;NA;NA;NA;16;-11,319;7,828;14;-3,021;7,48331477354788;NA;NA;NA;NA;33;3,9;16;27,6;6,6;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"mg 25";NA;"immediate group";"delayed group";1;44,1266666666667;0,391333333333333;"trd";NA;"crossover";"open-label";101016;5029466;"Rosenblat2024_change_madrs_Day7_1.00_clinician_psil_wl_NA_NA";1,05265203301189;0,391710041145542;NA;NA;NA;NA;NA;NA;"Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., â€¦ McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005"
"158";"Rosenblat, 2024";"psil";"wl";NA;NA;"change";"madrs";"clinician";"depression";1;"Post-first dose 3";14;2;14;1;0;NA;NA;NA;NA;NA;NA;16;-9,6;7,6;14;-3;3,36749164809655;NA;NA;NA;NA;33;3,9;16;27,6;6,6;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"mg 25";NA;"immediate group";"delayed group";1;44,1266666666667;0,391333333333333;"trd";NA;"crossover";"open-label";101016;5029466;"Rosenblat2024_change_madrs_Day14_2.00_clinician_psil_wl_NA_NA";1,06719381767744;0,392402176392329;NA;NA;NA;NA;NA;NA;"Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., â€¦ McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005"
"159";"Rosenblat, 2024";"psil";"wl";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 3";14;2;14;1;0;16;18;12,227;14;23,44;8,695;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;3,9;16;27,6;6,6;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"mg 25";NA;"immediate group";"delayed group";1;44,1266666666667;0,391333333333333;"trd";NA;"crossover";"open-label";101016;5029466;"Rosenblat2024_msd_madrs_Day14_2.00_clinician_psil_wl_NA_NA";0,493164108340404;0,371766604636151;NA;NA;NA;NA;NA;NA;"Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., â€¦ McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005"
"160";"Rosenblat, 2024";"psil";"wl";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 1";1;0,14;1;0;0;16;19,723;12,227;14;26,536;8,695;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;3,9;16;27,6;6,6;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"mg 25";NA;"immediate group";"delayed group";1;44,1266666666667;0,391333333333333;"trd";NA;"crossover";"open-label";101016;5029466;"Rosenblat2024_imsd_madrs_Day1_0.14_clinician_psil_wl_NA_NA";0,617633652596171;0,375026061567632;NA;NA;NA;NA;NA;NA;"Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., â€¦ McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005"
"161";"Rosenblat, 2024";"psil";"wl";NA;NA;"imsd";"madrs";"clinician";"depression";1;"Post-first dose 2";7;1;7;0;0;16;21,681;12,227;14;24,579;8,695;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33;3,9;16;27,6;6,6;15;"Some concerns";"Low";"Low";"High";"Low";"High";2024;"psilocybin";"waitlist";"mg 25";NA;"immediate group";"delayed group";1;44,1266666666667;0,391333333333333;"trd";NA;"crossover";"open-label";101016;5029466;"Rosenblat2024_imsd_madrs_Day7_1.00_clinician_psil_wl_NA_NA";0,262718673891635;0,367618986406524;NA;NA;NA;NA;NA;NA;"Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., â€¦ McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005"
"162";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Pre-first dose 1";1;-0,14;-1;0;0;14;10,4;6,9070995359847;15;16,247;7,54457155841205;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_bdi_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA";0,784450404153408;0,386427045543218;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"163";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 1";1;0,14;1;0;0;14;4,188;6,9070995359847;15;12,034;6,95200510644231;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";1,10036887261462;0,400241252699935;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"164";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 2";2;2;14;0;0;14;6,636;7,15404892351178;14;13,449;7,52073134741562;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_bdi_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA";0,901205879450261;0,397798255450695;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"165";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 3";6;6;42;0;0;14;6,438;6,71627500925922;14;14,181;6,9070995359847;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_bdi_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA";1,1035060876199;0,407340792292258;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"166";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-first dose 4";7;7;49;1;0;12;7,097;6,39473158154429;14;12,841;7,48331477354788;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";0,794044946587193;0,409500561347812;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"167";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-second dose 2";6;6;42;0;1;12;6,212;6,57486486553146;11;9,545;6,80571406980928;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_bdi_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA";0,480501399605098;0,423845590912223;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"168";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"bdi";"self-report";"depression";1;"Post-second dose 3";26;26;182;0;1;11;6,41;6,46078509161232;12;8,974;6,92820323027551;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";0,3683220830553;0,421208871873938;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"169";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Pre-first dose 1";1;-0,14;-1;0;0;14;3,859;3,47974136969977;15;5,945;3,40435236131632;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_hads-d_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA";0,589246817928049;0,380042102654754;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"170";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 1";1;0,14;1;0;0;14;2,019;3,38245827764364;15;6,164;3,21070319400595;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";1,2228754027737;0,406678447909128;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"171";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 2";2;2;14;0;0;14;2,109;3,43484148105848;14;5,831;3,43484148105848;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_hads-d_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA";1,05204046618656;0,404752847895918;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"172";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 3";6;6;42;0;0;14;2,263;3,47974136969977;14;6,761;3,1018339736356;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_hads-d_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA";1,32485277849218;0,419653953725893;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"173";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-first dose 4";7;7;49;1;0;12;2,734;3,30821704245656;14;6,101;3,28891684297429;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";0,988749055150377;0,418101050737959;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"174";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-second dose 2";6;6;42;0;1;12;1,791;3,30821704245656;11;4,906;3,16737667478941;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_hads-d_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA";0,926122719555942;0,4408092533097;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"175";"Ross, 2016";"psil";"ncn";NA;NA;"msd";"hads-d";"self-report";"depression";0;"Post-second dose 3";26;26;182;0;1;11;1,96;3,33320791430718;12;4,271;3,30821704245656;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_msd_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";0,67089618622881;0,429854469566899;NA;NA;NA;NA;NA;NA;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"176";"Ross, 2016";"psil";"ncn";NA;NA;"response";"bdi";"self-report";"depression";1;"Post-first dose 1";1;0,14;1;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_response_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";1,50223974351906;0,530033969845441;1,16760516015506;0,441857550844268;12;4;14;15;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"177";"Ross, 2016";"psil";"ncn";NA;NA;"response";"bdi";"self-report";"depression";1;"Post-first dose 4";7;7;49;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_response_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";1,81596223568403;0,599741779377007;1,76358859226136;0,667261639267608;10;2;12;14;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"178";"Ross, 2016";"psil";"ncn";NA;NA;"response";"bdi";"self-report";"depression";1;"Post-second dose 3";26;26;182;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_response_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";0,620466952517662;0,538490090853892;0,338325805270536;0,282357627355504;9;7;11;12;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"179";"Ross, 2016";"psil";"ncn";NA;NA;"remission";"hads-d";"self-report";"depression";0;"Post-first dose 1";1;0,14;1;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_remission_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";1,43912322147628;0,50557463670514;1,36827585561721;0,534927271829719;11;3;14;15;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"180";"Ross, 2016";"psil";"ncn";NA;NA;"remission";"hads-d";"self-report";"depression";0;"Post-first dose 4";7;7;49;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_remission_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";0,523682892597378;0,450158158078553;0,441832752279039;0,370006434950477;8;6;12;14;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"181";"Ross, 2016";"psil";"ncn";NA;NA;"remission";"hads-d";"self-report";"depression";0;"Post-second dose 3";26;26;182;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_remission_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";0,620466952517662;0,538490090853892;0,338325805270536;0,282357627355504;9;7;11;12;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"182";"Ross, 2016";"psil";"ncn";NA;NA;"response";"hads-d";"self-report";"depression";0;"Post-first dose 1";1;0,14;1;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_response_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";1,43912322147628;0,50557463670514;1,36827585561721;0,534927271829719;11;3;14;15;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"183";"Ross, 2016";"psil";"ncn";NA;NA;"response";"hads-d";"self-report";"depression";0;"Post-first dose 4";7;7;49;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_response_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";0,523682892597378;0,450158158078553;0,441832752279039;0,370006434950477;8;6;12;14;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"184";"Ross, 2016";"psil";"ncn";NA;NA;"response";"hads-d";"self-report";"depression";0;"Post-second dose 3";26;26;182;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_response_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";0,620466952517662;0,538490090853892;0,338325805270536;0,282357627355504;9;7;11;12;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"185";"Ross, 2016";"psil";"ncn";NA;NA;"remission";"bdi";"self-report";"depression";1;"Post-first dose 1";1;0,14;1;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_remission_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA";1,50223974351906;0,530033969845441;1,16760516015506;0,441857550844268;12;4;14;15;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"186";"Ross, 2016";"psil";"ncn";NA;NA;"remission";"bdi";"self-report";"depression";1;"Post-first dose 4";7;7;49;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_remission_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA";1,81596223568403;0,599741779377007;1,76358859226136;0,667261639267608;10;2;12;14;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"187";"Ross, 2016";"psil";"ncn";NA;NA;"remission";"bdi";"self-report";"depression";1;"Post-second dose 3";26;26;182;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,92;6,95200510644231;15;"Low";"Low";"Low";"Some concerns";"Some concerns";"Some concerns";2016;"psilocybin";"niacin";"mg 0.3/kg";"mg 250";"Psilocybin 1st group";"Niacin 1st group";1;56,0016129032258;0,611290322580645;"cancer";NA;"crossover";"double-blind";101177;957359;"Ross2016_remission_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA";0,620466952517662;0,538490090853892;0,338325805270536;0,282357627355504;9;7;11;12;"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165â€“1180. https://doi.org/10.1177/026988111667551"
"188";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"Pre-first dose 1";-1;-0,14;-1;0;NA;26;25,695;6,31768517734146;26;24,798;10,0195733442098;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_bdi_Day-1_-0.14_self-report_psil_pcb_NA_NA";-0,105480910024008;0,277548842334483;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"189";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"DOSE 1";0;0;0;0;NA;26;12,242;7,18961751416583;26;20,191;10,8915056810342;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_bdi_Day0_0.00_self-report_psil_pcb_NA_NA";0,848405368455339;0,289926959286354;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"190";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-first dose 1";2;0,29;2;0;NA;26;11,823;8,93348218781456;26;22,293;11,7685370373721;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_bdi_Day2_0.29_self-report_psil_pcb_NA_NA";0,987034352648897;0,294244283502394;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"191";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-first dose 2";8;1,14;8;0;NA;26;13,584;11,5492791982877;26;21,148;11,5492791982877;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_bdi_Day8_1.14_self-report_psil_pcb_NA_NA";0,645059290830097;0,284688371674402;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"192";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"bdi";"self-report";"depression";0;"Post-first dose 3";14;2;14;1;NA;26;13,379;10,2388311832943;26;20,729;11,3300213592032;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA";0,67040650657638;0,285268239079986;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"193";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"Pre-first dose 1";-1;-0,14;-1;0;NA;26;23,534;4,18629502065968;26;24,948;7,44456848984546;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_madrs_Day-1_-0.14_clinician_psil_pcb_NA_NA";0,230602854318363;0,278298712350879;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"194";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"DOSE 1";0;0;0;0;NA;26;11,727;7,21511261173379;26;21,034;9,53516649041851;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_madrs_Day0_0.00_clinician_psil_pcb_NA_NA";1,0841621390941;0,297613339412923;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"195";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 1";2;0,29;2;0;NA;26;9,775;7,90857926558241;26;20,632;11,1668527347682;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_madrs_Day2_0.29_clinician_psil_pcb_NA_NA";1,10515607016574;0,29837774449248;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"196";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 2";8;1,14;8;0;NA;26;12,065;8,8366008170563;26;19,957;10,468287061406;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_madrs_Day8_1.14_clinician_psil_pcb_NA_NA";0,802429725155049;0,288626644278412;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"197";"vonRotz, 2023";"psil";"pcb";NA;NA;"msd";"madrs";"clinician";"depression";1;"Post-first dose 3";14;2;14;1;NA;26;11,162;9,76972138804378;26;20,696;10,2388311832943;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_msd_madrs_Day14_2.00_clinician_psil_pcb_NA_NA";0,938367882310989;0,292661784694183;NA;NA;NA;NA;NA;NA;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"198";"vonRotz, 2023";"psil";"pcb";NA;NA;"response";"madrs";"clinician";"depression";1;"Post-first dose 3";14;2;14;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;26;4;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_response_madrs_Day14_2.00_clinician_psil_pcb_NA_NA";1,09412740860668;0,371085838569234;1,32175583998232;0,489636180999311;15;4;26;26;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"199";"vonRotz, 2023";"psil";"pcb";NA;NA;"remission";"madrs";"clinician";"depression";1;"Post-first dose 3";14;2;14;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_remission_madrs_Day14_2.00_clinician_psil_pcb_NA_NA";1,18976883955491;0,401968864868958;1,54044504094715;0,572572115841165;14;3;26;26;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"200";"vonRotz, 2023";"psil";"pcb";NA;NA;"response";"bdi";"self-report";"depression";0;"Post-first dose 3";14;2;14;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_response_bdi_Day14_2.00_self-report_psil_pcb_NA_NA";1,18976883955491;0,401968864868958;1,54044504094715;0,572572115841165;14;3;26;26;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
"201";"vonRotz, 2023";"psil";"pcb";NA;NA;"remission";"bdi";"self-report";"depression";0;"Post-first dose 3";14;2;14;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;26;3;26;26,541;6,31768517734146;26;25,9;10,0246723637234;26;"Low";"Low";"Low";"Some concerns";"Low";"Some concerns";2023;"psilocybin";"mannitol";"mg 0.215/kg";NA;"psilocybin group";"placebo group";1;36,75;0,6345;"dep";NA;"parallel";"double-blind";101016;3715127;"vonRotz2023_remission_bdi_Day14_2.00_self-report_psil_pcb_NA_NA";1,02235583542039;0,401968864868958;1,38629436111989;0,582875278034323;12;3;26;26;"von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., JÃ¤ncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809"
